EpiVax. has filed a patent for compositions containing regulatory T-cell epitopes, specifically a polypeptide consisting of certain amino acid sequences. The polypeptide can be linked to a heterologous polypeptide and may include additional amino acids. Methods of using these compositions are also disclosed. GlobalData’s report on EpiVax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EpiVax, Peptide pharmacophores was a key innovation area identified from patents. EpiVax's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a polypeptide with t-cell epitopes
A recently filed patent (Publication Number: US20230279072A1) describes a polypeptide that includes T-cell epitope polypeptides linked to a heterologous polypeptide. The T-cell epitope polypeptide can consist of specific amino acid sequences, such as SEQ ID NOS: 1, 8, 117, 118, 119, or combinations thereof. Additionally, the polypeptide may contain 1 to 12 additional amino acids distributed on the N terminus and/or C-terminus of the polypeptide. The T-cell epitope polypeptide can be linked to the N-terminus or C-terminus of the heterologous polypeptide, or fused to or inserted internally within it.
The heterologous polypeptide in the composition can be a blood component, such as albumin, transferrin, ferritin, or immunoglobulin. Alternatively, it can be a human serum albumin (HSA). The heterologous polypeptide is operatively linked to the T-cell epitope polypeptide.
The patent also covers a pharmaceutical composition that includes the polypeptide described above, along with one or more pharmaceutically acceptable excipients. Additionally, the composition may contain one or more adjuvants.
Furthermore, the patent describes a method of inducing regulatory T-cells to suppress immune response in a subject. This method involves administering a therapeutically effective amount of the polypeptide composition described earlier. The T-cell epitope polypeptide can be fused to the N-terminus or C-terminus of the heterologous polypeptide, or inserted internally within it. The heterologous polypeptide can be a blood component or a human serum albumin. The polypeptide composition may also include one or more antigens and/or allergens, and it can promote antigen-specific tolerance and prolong the half-life of the antigen and/or allergen. Additionally, the composition can suppress effector T-cell and helper T-cell responses.
In summary, this patent describes a polypeptide composition that includes T-cell epitope polypeptides linked to a heterologous polypeptide, which can be a blood component or a human serum albumin. The composition can be used in pharmaceutical compositions and methods for inducing regulatory T-cells and suppressing immune responses.
To know more about GlobalData’s detailed insights on EpiVax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
